Program
fexofenadine
Also written as “Fexofenadine”, “Fexofenadine Tablets 180 mg” and “fexofenadine/Allegra (M016455)”.
Its studies are mostly in Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Rhinitis, Allergic, Perennial · Rhinitis · Asthma, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 160 open or running | phase 4since Mar 10, 2008 | Sep 5, 2002 | none ahead |
| Dr. Reddy's Laboratories | 50 open or running | phase 1since Feb 9, 2010 | Feb 9, 2010 | none ahead |
| Organon | 30 open or running | phase 4since Oct 30, 2008 | Oct 30, 2008 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
| Viatris | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Bayer | 10 open or running | phase 4since Nov 8, 2011 | Nov 8, 2011 | none ahead |
| Handok | 10 open or running | phase 4since Dec 1, 2005 | Dec 1, 2005 | none ahead |
Also a collaborator on its studies: achillion-a-wholly-owned-subsidiary-of-alexion.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Sep 5, 2002.
- Aug 22, 2008Phase 4 study in Rhinitis, Allergic, PerennialSanofi · NCT00741897 · 264 enrolled · Philippines
- Oct 30, 2008Organon's first study: phase 4 study in Rhinitis, Allergic, SeasonalNew to OrganonOrganon · NCT00783133 · 131 enrolled
- Nov 19, 20082 phase 4 studies in Rhinitis, Allergic, SeasonalOrganon · NCT00794768, NCT00794248
- Jan 30, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00835640, NCT00835276
- Feb 9, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01066767, NCT01066754
- May 27, 20102 phase 1 studies in HealthyDr. Reddy's Laboratories · NCT01133483, NCT01133470
- Nov 15, 20102 phase 3 studiesSanofi · NCT01244230, NCT01244217
- Mar 1, 2011Phase 3 study in Rhinitis SeasonalSanofi · NCT01306721 · 520 enrolled · Japan
- Nov 8, 2011Bayer's first study: phase 4 study in RhinitisNew to BayerBayer · NCT01469234 · 255 enrolled
- Jun 26, 2013Phase 1 study in HealthyDr. Reddy's Laboratories · NCT01888718 · 80 enrolled · India
- Jun 22, 2014Phase 4 study in Rhinitis, Allergic, PerennialSanofi · NCT02175485 · 24 enrolled · Japan
- Jan 11, 2023Phase 3 study in Rhinitis, Allergic, SeasonalSanofi · NCT05692154 · 95 enrolled · Canada
- Jan 31, 2023Phase 4 study in Rhinitis, Allergic, PerennialSanofi · NCT05720455 · 203 enrolled · India
- Feb 22, 2024Phase 1 study in Healthy VolunteersSanofi · NCT06284902 · 25 enrolled · Canada
TargetBeta
“Histamine H1 receptor antagonist”ChEMBL 37, by rule
Other programs on HRH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| desloratadinerule | Organon | phase 4 | 40 |
| bilastinerule | faes-farma-s-a | phase 4 | 19 |
| Diphenhydraminerule | Johnson & Johnson | phase 4 | 16 |
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06284902Healthy Volunteers · Canada | 1 | Completed | Sanofi | May 8, 2024 | 25 |
| NCT05720455Rhinitis, Allergic, Perennial · India | 4 | Completed | Sanofi | Dec 5, 2025 | 203 |
| NCT05692154Rhinitis, Allergic, Seasonal · Canada | 3 | Completed | Sanofi | Mar 14, 2023 | 95 |
| NCT02175485Rhinitis, Allergic, Perennial · Japan | 4 | Completed | Sanofi | Jun 2014 | 24 |
| NCT01888718Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Feb 2011 | 80 |
| NCT01469234Rhinitis | 4 | Completed | Bayer | Nov 2011 | 255 |
| NCT01306721Rhinitis Seasonal · Japan | 3 | Completed | Sanofi | Apr 2011 | 520 |
| NCT01244230Dermatitis, Atopic · Japan | 3 | Completed | Sanofi | Jul 2011 | 100 |
| NCT01244217Rhinitis Perennial · Japan | 3 | Completed | Sanofi | Jul 2011 | 100 |
| NCT01133483Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Apr 2007 | 38 |
| NCT01133470Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Feb 2007 | 54 |
| NCT01066767Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | May 2002 | 30 |
| NCT01066754Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | May 2002 | 44 |
| NCT00835640Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jan 2002 | 24 |
| NCT00835276Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Mar 2002 | 60 |
| NCT00794768Rhinitis, Allergic, Seasonal | 4 | Completed | Organon | Jul 2003 | 118 |
| NCT00794248Rhinitis, Allergic, Seasonal | 4 | Completed | Organon | May 2003 | 122 |
| NCT00783133Rhinitis, Allergic, Seasonal | 4 | Completed | Organon | Jun 1, 2003 | 131 |
| NCT00741897Rhinitis, Allergic, Perennial · Philippines | 4 | Completed | Sanofi | Dec 2003 | 264 |
| NCT00649376Healthy · United States | 1 | Completed | Viatris | Nov 2003 | 68 |
| NCT00647985Healthy · United States | 1 | Completed | Viatris | Nov 2003 | 28 |
| NCT00638118Rhinitis, Allergic · United States | 4 | Completed | Sanofi | 48 | |
| NCT00637884Cat Induced Allergic Rhinitis | 4 | Completed | Sanofi | 70 | |
| NCT00637611Rhinitis, Allergic, Seasonal · United States | 4 | Completed | Sanofi | 1,010 | |
| NCT00637585Rhinitis, Allergic · United States | 4 | Completed | Sanofi | 42 | |
| NCT00637455Rhinitis, Allergic, Seasonal · United States | 4 | Completed | Sanofi | 72 | |
| NCT00636870Rhinitis, Allergic · United States | 4 | Completed | Sanofi | 220 | |
| NCT00261079Pruritus · Korea, Republic of | 4 | Completed | Handok | 435 | |
| NCT00044824Asthma · United States, Costa Rica, Guatemala and more | 3 | Completed | Sanofi | Oct 2003 | 1,000 |
| NCT00044811Asthma · United States, Costa Rica, Guatemala and more | 3 | Completed | Sanofi | Oct 2003 | 1,000 |
How it is read
Names in the registry
- “Fexofenadine”, 14 entries
- “fexofenadine”, 4 entries
- “Fexofenadine Tablets 180 mg”, 2 entries
- “fexofenadine/Allegra (M016455)”, 2 entries
- “Fexofenadine HCl”, 2 entries
Conditions, from the studies’ own filings
- Rhinitis, Allergic, Seasonal, 8 studies
- Rhinitis, Allergic, 5 studies
- Rhinitis, Allergic, Perennial, 3 studies
- Rhinitis, 3 studies
- Asthma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.